Monitoring Camizestrant Safety in Community Oncology Practice

Carol Tweed, MD, tells community oncologists that camizestrant's cardiac and ocular effects do not require routine referral to cardiology or ophthalmology, calling asymptomatic bradycardia and photopsia a non-issue that does not impair patient function and tends to resolve over time. She reports that patients who switched to camizestrant on trial had significant improvement in arthralgia at baseline, a finding she considers underrepresented in reported trial data, and did not see the trigger finger sometimes seen with aromatase inhibitors. Rebecca Shatsky, MD, agrees, noting improved hand symptoms reported by patients who work with their hands professionally. Neil Iyengar, MD, suggests current patient-reported outcome instruments may not be granular enough to separate arthralgia from other musculoskeletal symptoms and proposes borrowing more detailed assessment tools from rheumatology to better capture these differences in future studies.